Celldex Therapeutics Inc
SWB:TCE2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Celldex Therapeutics Inc
SWB:TCE2
|
US |
|
C
|
Coty Inc
F:CO3A
|
US |
|
Impala Platinum Holdings Ltd
F:IPH1
|
ZA |
|
Anpario PLC
F:KI9A
|
UK |
|
Celldex Therapeutics Inc
NASDAQ:CLDX
|
US |
|
W
|
Williams Companies Inc
XHAM:WMB
|
US |
|
Haitong Securities Co Ltd
F:6HT
|
CN |
|
Trimble Inc
NASDAQ:TRMB
|
US |
|
Exxaro Resources Ltd
OTC:EXXAF
|
ZA |
Wall St Price Targets
TCE2 Price Targets Summary
Celldex Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
TCE2 is 52.06 EUR with a low forecast of 33.53 EUR and a high forecast of 82.55 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is TCE2's stock price target?
Price Target
52.06
EUR
According to Wall Street analysts, the average 1-year price target for
TCE2 is 52.06 EUR with a low forecast of 33.53 EUR and a high forecast of 82.55 EUR.
What is the Revenue forecast for Celldex Therapeutics Inc?
Projected CAGR
375%
Over the last 13 years, the compound annual growth rate for Revenue has been -14%. The projected CAGR for the next 3 years is 375%.